Trial Profile
A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms JAVELIN Renal 100
- Sponsors Pfizer
- 06 Jun 2023 Results of pooled exploratory analysis (n=2631 from four studies (KEYNOTE-426, JAVELIN Renal 100, CheckMate 9ER, CheckMate 214) assessing relationship of week 12 DepOR as a continuous variable with OS, hypothesizing not only complete but also deep partial responses might portend favorable longer-term survival in frontline advanced immuno-oncology renal cell carcinoma trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results of a pooled exploratory analysis assessing treatment free survival (TFS) with and without ongoing toxicity in addition to time on protocol therapy from three clinical trials: KEYNOTE-426, JAVELIN Renal 100 and CheckMate 9ER presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Apr 2023 Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial assessing long-term safety and efficacy of avelumab plus axitinib as first-line treatment for patients with aRCC published in the Oncologist